Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla
✍ Scribed by Zoran Rumboldt; Howard A. Rowley; Fred Steinberg; Joseph A. Maldjian; Jordi Ruscalleda; Lars Gustafsson; Stefano Bastianello
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 630 KB
- Volume
- 29
- Category
- Article
- ISSN
- 1053-1807
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Purpose
To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast‐enhanced MRI of brain lesions at 3 Tesla (T).
Materials and Methods
Forty‐six randomized patients underwent a first examination with gadobenate dimeglumine (n = 23) or gadopentetate dimeglumine (n = 23) and then, after 2–7 days, a second examination with the other agent. Contrast administration (volume, rate), sequence parameters (T1wSE; T1wGRE), and interval between injection and image acquisition were identical for examinations in each patient. Three blinded neuroradiologists evaluated images qualitatively (lesion delineation, lesion enhancement, global preference) and quantitatively (lesion‐to‐brain ratio [LBR], contrast‐to‐noise ratio [CNR], % lesion enhancement). Differences were assessed using Wilcoxon's signed‐rank test. Reader agreement was determined using kappa (κ) statistics.
Results
There were no demographic differences between groups. The three readers preferred gadobenate dimeglumine globally in 22 (53.7%), 21 (51.2%), and 27 (65.9%) patients, respectively, compared with 0, 1, and 0 patients for gadopentetate dimeglumine. Similar significant (P < 0.001) preference was expressed for lesion border delineation and enhancement. Reader agreement was consistently good (κ = 0.48–0.64). Significantly (P < 0.05) higher LBR (+43.5– 61.2%), CNR (+51.3–147.6%), and % lesion enhancement (+45.9–49.5%) was noted with gadobenate dimeglumine.
Conclusion
Brain lesion depiction at 3T is significantly improved with 0.1 mmol/kg gadobenate dimeglumine. J. Magn. Reson. Imaging 2009;29:760–767. © 2009 Wiley‐Liss, Inc.